论文部分内容阅读
目的 探讨重组人生长激素对肝硬变低蛋白血症、腹水的疗效。方法 选择肝硬变腹水病人33例 ,随机分为重组人生长激素 (rhGH)治疗组 16例 ,对照组 17例。治疗组每晚睡前皮下注射rhGH 4U ,10d为 1个疗程 ;对照组每周补白蛋白 2 0g ,10d为 1个疗程。分别在治疗前、后检测两组的血浆白蛋白、空腹血糖、血脂并监测肾功能 ;观察 2 4h尿量及腹水的消退情况。结果 治疗后治疗组血浆白蛋白明显增加 ,腹水消退明显 ,与对照组相比差异有显著意义 (P均 <0 0 5 )。结论 重组人生长激素有明显促进肝硬变病人血清白蛋白合成的作用 ,具有临床应用价值。
Objective To investigate the effect of recombinant human growth hormone on cirrhosis with hypoproteinemia and ascites. Methods 33 patients with cirrhosis and ascites were randomly divided into 16 cases of rhGH treatment group and 17 cases of control group. The treatment group was injected with rhGH 4U subcutaneously every night before going to bed, and a course of treatment was given for 10 days. The control group received 20 g of albumin per week and a course of treatment was given for 10 days. The serum albumin, fasting blood glucose, blood lipid and renal function were measured before and after treatment respectively. The urinary output and the regression of ascites were observed 24 hours later. Results After treatment, the plasma albumin of the treatment group increased significantly, and the ascites subsided obviously. There was significant difference between the treatment group and the control group (all P <0.05). Conclusion Recombinant human growth hormone can significantly promote the serum albumin synthesis in cirrhotic patients, and has clinical value.